Trials / Conditions / Philadelphia Chromosome Positive

Philadelphia Chromosome Positive

18 registered clinical trials studyying Philadelphia Chromosome Positive — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphi NCT07178912	M.D. Anderson Cancer Center	Phase 2
Recruiting	Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Pos NCT06308588	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Recruiting	ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic NCT05007873	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymph NCT04329325	Memorial Sloan Kettering Cancer Center	Phase 2
Active Not Recruiting	Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leuke NCT03512405	City of Hope Medical Center	Phase 1 / Phase 2
Recruiting	Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood NCT03589729	M.D. Anderson Cancer Center	Phase 2
Terminated	ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia NCT03698552	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Terminated	Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Rela NCT03576547	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Terminated	EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acu NCT03519984	University of Southern California	Phase 1
Recruiting	Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positi NCT03263572	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refrac NCT03241940	Stanford University	Phase 1
Active Not Recruiting	CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refract NCT03233854	Stanford University	Phase 1
Completed	Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia NCT02997761	University of California, Davis	Phase 2
Completed	Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease NCT02458014	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia NCT01424982	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic NCT01190930	Children's Oncology Group	Phase 3
Completed	Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response NCT01043874	Novartis Pharmaceuticals	Phase 4
Completed	Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive NCT00390793	M.D. Anderson Cancer Center	Phase 2